Therapeutic drug monitoring of sertraline in children and adolescents: A naturalistic study with insights into the clinical response and treatment of obsessive-compulsive disorder
- PMID: 35248877
- DOI: 10.1016/j.comppsych.2022.152301
Therapeutic drug monitoring of sertraline in children and adolescents: A naturalistic study with insights into the clinical response and treatment of obsessive-compulsive disorder
Abstract
Background: Sertraline is a selective serotonin reuptake inhibitor with specific indications in child and adolescent psychiatry. Notwithstanding its frequent use and clinical benefits, the relationship between pharmacokinetics, pharmacodynamics, efficacy, and tolerability of sertraline across indications, particularly in non-adult patients, is not fully understood.
Method: This naturalistic therapeutic drug monitoring (TDM) study was conducted in a transdiagnostic sample of children and adolescents treated with sertraline (n = 78; mean age, 14.22 ± 2.39; range, 7-18 years) within the prospective multicenter "TDM-VIGIL" project. Associations between dose, serum concentration, and medication-specific therapeutic and side effects based on the Clinical Global Impression scale were examined. Tolerability was measured qualitatively with the 56-item Pediatric Adverse Event Rating Scale.
Results: A strong linear positive dose-serum concentration relationship (with dose explaining 45% of the variance in concentration) and significant effects of weight and co-medication were found. Neither dose nor serum concentration were associated with side effects. An overall mild-to-moderate tolerability profile of sertraline was observed. In contrast with the transdiagnostic analysis that did not indicate an effect of concentration, when split into depression (MDD) and obsessive-compulsive disorder (OCD) diagnoses, the probability of clinical improvement significantly increased as both dose and concentration increased for OCD, but not for MDD.
Conclusions: This TDM-flexible-dose study revealed a significant diagnosis-specific effect between sertraline serum concentration and clinical efficacy for pediatric OCD. While TDM already guides clinical decision-making regarding compliance, dose calibration, and drug-drug interactions, combining TDM with other methods, such as pharmacogenetics, may facilitate a personalized medicine approach in psychiatry.
Keywords: TDM; antidepressants; pharmacovigilance; selective serotonin reuptake inhibitors; steady state concentration.
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Similar articles
-
The relation between dosage, serum concentrations, and clinical outcome in children and adolescents treated with sertraline: a naturalistic study.Ther Drug Monit. 2013 Feb;35(1):84-91. doi: 10.1097/FTD.0b013e31827a1aad. Ther Drug Monit. 2013. PMID: 23318280
-
Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial.JAMA. 1998 Nov 25;280(20):1752-6. doi: 10.1001/jama.280.20.1752. JAMA. 1998. PMID: 9842950 Clinical Trial.
-
Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: pharmacokinetics, tolerability, and efficacy.J Am Acad Child Adolesc Psychiatry. 1998 Apr;37(4):386-94. doi: 10.1097/00004583-199804000-00016. J Am Acad Child Adolesc Psychiatry. 1998. PMID: 9549959 Clinical Trial.
-
A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.J Clin Psychiatry. 1999 Feb;60(2):101-6. doi: 10.4088/jcp.v60n0206. J Clin Psychiatry. 1999. PMID: 10084636 Review.
-
Sertraline in the treatment of obsessive compulsive disorder: two double-blind, placebo-controlled studies.Int Clin Psychopharmacol. 1992 Oct;7 Suppl 2:37-41. doi: 10.1097/00004850-199210002-00007. Int Clin Psychopharmacol. 1992. PMID: 1484177 Review.
Cited by
-
Machine Learning-Based Prediction of Escitalopram and Sertraline Side Effects With Pharmacokinetic Data in Children and Adolescents.Clin Pharmacol Ther. 2024 Apr;115(4):860-870. doi: 10.1002/cpt.3184. Epub 2024 Jan 31. Clin Pharmacol Ther. 2024. PMID: 38297828 Free PMC article.
-
Sex-Specific Differences in Antidepressant and Antipsychotic Treatment Outcomes and Serum Levels in Children and Adolescents.Pharmaceutics. 2025 Jul 30;17(8):983. doi: 10.3390/pharmaceutics17080983. Pharmaceutics. 2025. PMID: 40871006 Free PMC article.
-
Serum Concentration-Dose Relationship and Modulation Factors in Children and Adolescents Treated with Fluvoxamine.Pharmaceutics. 2024 Jun 6;16(6):772. doi: 10.3390/pharmaceutics16060772. Pharmaceutics. 2024. PMID: 38931893 Free PMC article.
-
Toward therapeutic drug monitoring of citalopram in depression? Insights from a systematic review.Front Psychiatry. 2023 Apr 27;14:1144573. doi: 10.3389/fpsyt.2023.1144573. eCollection 2023. Front Psychiatry. 2023. PMID: 37181880 Free PMC article.
-
The prevalence of off-label use and supratherapeutic blood levels of outpatient psychotropic medication in suicidal adolescents.Front Psychiatry. 2024 Jan 17;14:1240681. doi: 10.3389/fpsyt.2023.1240681. eCollection 2023. Front Psychiatry. 2024. PMID: 38298931 Free PMC article.